BioSpace News Archive

PANTHERx Rare announces that it has been selected by Aadi Bioscience as the exclusive U.S. pharmacy distribution partner for new drug FYARRO™ (sirolimus protein-bound particles for injectable suspension) (albumin-bound).

Generation Bio Co., a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, outlined its strategic priorities for 2022 and reported fourth quarter and full year 2021 financial results.

DBV Technologies, a clinical-stage biopharmaceutical company, announced that the Company will host a conference call and live audio webcast on Thursday, March 3, 2022 at 5:00 p.m. ET to report full year 2021 financial results and provide a corporate update.

Select Medical Holdings Corporation announced results for its fourth quarter and year ended December 31, 2021 and the declaration of a cash dividend.

4WEB Medical, an orthopedic device company focused on developing innovative implants with an Advanced Structural Design utilizing its proprietary Truss Implant Technology™, announced the company’s launch of a comprehensive array of hyperlordotic lateral implants.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and operational highlights for the period ended December 31, 2021.

Applied DNA Sciences, Inc. announced the closing of its previously announced registered direct offering with an institutional investor of 1,496,400 shares of common stock at a price of $2.80 per share for gross proceeds of approximately $4.2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.

Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced financial results for the quarter ended December 31, 2021 (the “third quarter”).

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend Pfizer’s TicoVacTM (tick-borne encephalitis (TBE) vaccine) for active immunization to prevent TBE in individuals 1 year of age and older.

Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company based in Weston, FL, announced that it has secured a global license from Harvard University’s Office of Technology Development (OTD) to further develop Cantex’s drug azeliragon into a treatment for inflammatory lung diseases including COVID-19.